Aurinia Pharmaceuticals to Present at the BIO CEO Investor Conference
VICTORIA, British Columbia-- Aurinia Pharmaceuticals, Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its President and Chief Executive Officer Stephen Zaruby will present a corporate overview of the company at the BIO CEO Investor Conference, taking place February 9th-10th in New York at the Waldorf-Astoria Hotel. The presentation will also be available using the webcast link below.
Aurinia Presentation Details
Date:
Tuesday, February 10th, 2015
Time: 3:00 p.m. Eastern
Standard Time
Location: Waldorf-Astoria Hotel
Webcast: http://www.veracast.com/webcasts/bio/ceoinvestor2015/69221498302.cfm
About Aurinia
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently in the recruitment and enrollment phase of its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis (LN). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals, Inc.
Company Contact:
Stephen
Zaruby, 250-708-4293
President & Chief Executive Officer
szaruby@auriniapharma.com
or
Investor
& Media Contact:
Michael R. Martin, 250-708-4272
Chief
Operating Officer
mmartin@auriniapharma.com
Source: Aurinia Pharmaceuticals, Inc.
Released January 29, 2015
